1st Faculty of Medicine Charles University 1st Faculty of Medicine Charles University BIOCEV
lvysa 08.09.2020

Stopka Lab

Publications (dedicated to NPU=N or Biocev=B, international collaboration=I, collaboration with hospital=H, from group in Inst.131/from Detached group)

2020


Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes. Pribyl M, Hubackova S, Moudra A, Vancurova M, Polackova H, Stopka T, Jonasova A, Bokorova R, Fuchs O, Stritesky J, Salovska B, Bartek J, Hodny Z. [published online ahead of print, 2020 Jul 21]. Mol Oncol. 2020;10.1002/1878-0261.12768. doi:10.1002/1878-0261.12768. (IF 6.574) [PubMed] (H, I, 131)

Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry. Minarik L, Vargova K, Dusilkova N, Kulvait V, Jonasova Am Kodet O, Stopka T. Folia Biol (Praha). 2020;66(1):1-6. (IF 1.073) [Pubmed] (H, 131)

Universal promoter scanning by Pol II during transcription initiation in Saccharomyces cerevisiae. Qiu C, Jin H, Vvedenskaya I, Llenas JA, Zhao T, Malik I, Visbisky AM, Schwartz SL, Cui P, Čabart P, Han KH, Lai W, Metz RP, Johnson CD, Sze SH, Pugh BF, Nickels BE & Kaplan, CD (2020). Genome biology, 21(1), 132. https://doi.org/10.1186/s13059-020-02040-0. (IF 14.028) [PubMed] (131)

Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits Proliferation and Chromatid Cohesion. Zikmund T, Paszekova H, Kokavec J, Kerbs P, Thakur S, Turkova T, Tauchmanova P, Greif PA, Stopka TInt J Mol Sci. 2020;21(6):E2073. Published 2020 Mar 18. doi:10.3390/ijms21062073. (IF 4.183) [PubMeb] (B, N, I, H, 131)

The chromatin remodeler Snf2h is essential for oocyte meiotic cell cycle progression. Zhang C, Chen Z, Yin Q, Fu X, Li Y, Stopka T, Skoultchi A, Zhang Y. Genes Dev. 2020;34(3-4):166–178. doi:10.1101/gad.331157.119. (IF 8.990)[PubMed] (I, H)

2019

ISWI ATPase Smarca5 Regulates Differentiation of Thymocytes Undergoing β-Selection. Zikmund T, Kokavec J, Turkova T, Savvulidi F, Paszekova H, Vodenkova S, Sedlacek R, Skoultchi AI, Stopka T. J Immunol. 2019 Jun 15;202(12):3434-3446. doi: 10.4049/jimmunol.1801684. (IF 4.539)[PubMed](B, N, I, 131)

Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance (MGUS): clinical findings in twelve patients including recurrence after keratoplasty. Skalicka P, Dudakova L, Palos M, Huna L, Evans CJ, Mahelkova G, Meliska M, Stopka T, Tuft S, Liskova P. Acta Ophthalmologica. In Press. (IF 3.032) [PubMed] (I, H, 131)

Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS. Minarik L, Zemanova Z, Kulvait V, Dluhosova M, Jonasova A and Stopka T. Ann Hematol Oncol. 2019; 6(1): 0000. (IF 2.219) [PDF] (N, B, H, 131)

Randomizovaná otevřená akademická studie: srovnání standardního podání azacytidinu oproti azacytidinu s preinkubací G-CSF u myelodysplastického syndromu vyššího rizika – interim analýza. Stopka T, Minarik L, Kulvait V, Pesta M, Schaffartzikova A, Kislik G, Dusilkova N, Zemanova Z, Jonasova A. Myelodysplastic Syndrome NEWS. Ročník 7 / číslo 2 / listopad 2019. (131)

2018

Akutní myeloidní leukémie - Novinky v diagnostice a léčbě. Stopka T. Event Report z EHA 2018. [PDF] (N, 131)

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Machova Polakova K. Haematologica. 2018 Jul 26. pii: haematol.2018.193086. doi: 10.3324/haematol.2018.193086. (IF 9.09) [PubMed] (I, 131)

Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin±prednisone addition to lenalidomide in refractory or relapsed patients). Jonasova A, Neuwirtova R, Polackova H, Siskova M, Stopka T, Cmunt E, Belickova M, Moudra A, Minarik L, Fuchs O, Michalova K, Zemanova Z. Leukemia Research 69 (2018) 12-17. 2018 March 27. https://doi.org/10.1016/j.leukres.2018.03.015 . (IF 2.319) [PDF] (H, 131)

1. interim analýza randomizované otevřené klinické studie GA-MDS/2013. Dusilkova N, Minarik L, Stopka T, Jonasova A. Myelodysplastic Syndrome NEWS. Ročník 6 / Číslo 1 / květen 2018. [PDF] (N, 131)

2017

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders. Polgarova K, Vargova K, Kulvait V, Dusilkova N, Minarik L, Zemanova Z, Pesta M, Jonasova A and Stopka T. Oncotarget. 2017 Dec 6. (IF 5.168) [PDF] (B, N, H, 131)

Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer. Basova P, Pesta M, Sochor M, Stopka T. Int J Mol Sci. 2017 Oct 10;18(10). pii: E2116. doi: 10.3390/ijms18102116. (IF 3.226)[PDF](B, N, H, 131)

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-cell Lymphomas. Dusilkova N, Basova P, Polivka J, Kodet O, Kulvait V, Pesta M, Trneny M, Stopka T. Int J Mol Sci. 2017 Oct 15;18(10). pii: E2136. doi: 10.3390/ijms18102136. (IF 3.226) [PDF] (B, N, H, 131)

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.Vargova K, Pesta M, Obrtlikova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M, Stopka T.  Blood Cancer J. 2017 Jul 21;7(7):e585. doi: 10.1038/bcj.2017.63. (IF 6.126) [PDF] (B, N, H, 131)

Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. Huskova H, Ardin M, Weninger A, Vargova K, Barrin S, Villar S, Olivier M, Stopka T, Herceg Z, Hollstein M, Zavadil J, Korenjak M. Oncogene. 2017 Jul 10. (IF 7.519) [PDF] (B, N, I, 131)

Využití detekce somatických mutací pro pacienty s cytopenií nejasného významu a u myelodysplastického syndromu. Stopka T. Myelodysplastic Syndrome NEWS. Ročník 5 / Číslo 1 / květen 2017. [PDF] (N, 131)

The ISWI ATPase Smarca (Snf2h) Is Required for Proliferation and Differentiation of Hematopoietic Stem and Progenitor Cells. Kokavec J, Zikmund T, Savvulidi F, Kulvait V, Edelmann W, Skoultchi AI, Stopka T.  Stem Cells. 2017 Mar 9. doi: 10.1002/stem.2604. (IF 5.599) [PDF] (B, N, I, 131)

2016

Somatické mutace u myelodysplastického syndromu a jejich klinické využití. Tomáš Stopka. Myelodysplastic Syndrome NEWS. Ročník 4 / Číslo 2 / listopad 2016 [PDF] (N, 131)

Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: evidence for co-repressor functions. DN Papageorgiou, E Karkoulia, A Amaral-Psarris, P Burda, K Kolodziej, JA Demmers, J Bungert, T Stopka, J Strouboulis. Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, accepted (IF: 5.373) [PDF] (N, B, I, H, 131)

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia. Vargova J, Vargova K, Dusilkova N, Kulvait V, Pospisil V, Zavadil J, Trneny M, Klener P, Stopka T. Blood Cancer J. 2016 Sep 23;6(9):e475. (IF 4.411) [PDF] (N, B, I, H, 131)

GATA-1 inhibits PU.1 gene via DNA and histone H3K9 Methylation of its Distal Enhancer in Erythroleukemia. P Burda, J. Vargova, N Curik, C Salek, G Papadopoulos, J Strouboulis and T. Stopka. PLoS One, 2016 Mar 24;11(3):e0152234. (IF 3.234) [PDF] (B, N, I, H, 131)

Chromatin remodeling enzyme Snf2h/Smarca5 regulates embryonic lens differentiation and denucleation. Shuying He, Saima Limi, Rebecca S. McGreal, Qing Xie, Lisa A. Brennan, Wanda Lee Kantorow, Juraj Kokavec, Romit Majumdar, Harry Hou, Jr, Winfried Edelmann, Wei Liu, Ruth Ashery-Padan, Jiri Zavadil, Marc Kantorow, Arthur Skoultchi, Tomas Stopka, and Ales Cvekl. Development. 2016 Jun 1;143(11):1937-47. (IF 6.462) [PDF] (B, N, I, 131)